Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Konpa

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Internal Medicine Journal|March 18, 2010
Factitious hypoglycaemiaC Yates, S Neoh, A Konpa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trialN Harbeck, S Modi, L Pusztai, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Internal Medicine Journal|March 18, 2010
Factitious hypoglycaemiaC Yates, S Neoh, A Konpa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trialN Harbeck, S Modi, L Pusztai, et al.
Pageof 1